Clinical Trials on Subjects With NSCLC With an EGFR Activating Mutation
Total 53 results
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
Coloplast A/SCompletedSubjects With an IleostomyDenmark
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
Medtronic - MITGCompletedSubjects With an Existing Intra-arterial LineUnited States
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Français de Pneumo-CancérologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
Astellas Pharma IncTerminatedEGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating MutationsJapan
-
The University of Hong KongUnknownNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIBHong Kong
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
-
Peking Union Medical CollegeRecruitingNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, RecurrentChina
-
Fudan UniversityCompletedNSCLC Stage IV | EGFR Activating MutationChina
-
Yonsei UniversityUnknownCompletely Resected NSCLC With Common EGFR MutationsKorea, Republic of
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
Blueprint Medicines CorporationActive, not recruitingNeoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditionsUnited States, Canada, Korea, Republic of, Japan, Taiwan
-
TYK Medicines, IncRecruitingNSCLC | EGFR Activating MutationChina
-
Second Affiliated Hospital of Nanchang UniversityJiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingNSCLC | EGFR Activating Mutation | Leptomeningeal MetastasisChina
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France
-
Arog Pharmaceuticals, Inc.CompletedNewly Diagnosed AML With FLT3 Activating MutationsUnited States
-
PfizerCompletedNon-small Cell Lung Cancer With EGFR-Activating MutationsItaly, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
-
Servier Bio-Innovation LLCInstitut de Recherches Internationales ServierNot yet recruitingLocally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
-
TYK Medicines, IncRecruitingNSCLC | Brain Metastases | EGFR Activating MutationChina
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
Arog Pharmaceuticals, Inc.RecruitingRelapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States, Germany, Spain, Italy, France, Canada
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
Radiotherapy Oncology Centre "Santa Maria" HospitalPaola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MDRecruitingNSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditionsItaly
-
First People's Hospital of HangzhouHangzhou Cancer HospitalRecruitingNon Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLCChina
-
TYK Medicines, IncActive, not recruitingNSCLC | Brain Metastases | EGFR Activating Mutation | Leptomeningeal MetastasisChina
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
AstraZenecaCompletedCarcinoma, Non-Small-Cell Lung With EGFR Mutation PositiveChina
-
AIO-Studien-gGmbHAstraZenecaTerminatedNSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR MutationGermany
-
Suzhou Genhouse Bio Co., Ltd.RecruitingNon-Small Cell Lung Cancer With EGFR MutationChina
-
H. Lee Moffitt Cancer Center and Research InstituteBlueprint Medicines CorporationRecruitingSystemic Mastocytosis With an Associated Hematologic NeoplasmUnited States
-
Universität Duisburg-EssenTerminatedNon-small-cell Lung Cancer With Somatic EGFR Mutations
-
Sichuan Provincial People's HospitalUnknownStage IV EGFR Mutated NSCL With Brain MetastasesChina
-
AIO-Studien-gGmbHBoehringer IngelheimTerminatedNon-small-cell Lung Cancer With Somatic EGFR MutationsGermany
-
Shanghai Chest HospitalRecruitingMetastatic Cancer | Adenocarcinoma of Lung | Non-Small Cell Lung Cancer With EGFR Mutation | Locally Advanced Solid TumorChina
-
Instituto Nacional de Cancerologia de MexicoRecruitingNon-Small Cell Lung Cancer With EGFR MutationMexico
-
Guangzhou Institute of Respiratory DiseaseShanghai Junshi Bioscience Co., Ltd.UnknownIIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib TherapyChina
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationUnited States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
-
Axcella Health, IncCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease | Sickle Cell DisordersUnited States
-
Centre hospitalier de l'Université de Montréal...CompletedQT and Corrected QT Intervals Prolongation in HIV Positive Subjects Treated With an Antiretroviral RegimenCanada
-
Samsung Medical CenterActive, not recruitingNon-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase InhibitorsKorea, Republic of
-
PlexxikonTerminatedSolid Tumor | Tenosynovial Giant Cell Tumor | Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion MutationsUnited States
-
Blueprint Medicines CorporationActive, not recruitingMast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematologic NeoplasmUnited States, Canada, United Kingdom, France, Netherlands, Italy, Spain, Austria, Denmark, Germany, Norway, Poland
-
Fujian Cancer HospitalNot yet recruitingNon-small Cell Lung Cancer Confirmed by Histopathology or Cytology | The TNM (8th) Phase is IV | With EGFR Mutations | Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment | Male or Female | The Age of 18 Years Old or... and other conditions
-
Medolution Ltd.RecruitingBrain Metastases | Non-Small Cell Lung Cancer With EGFR MutationChina
-
Cogent Biosciences, Inc.RecruitingAdvanced Systemic Mastocytosis (AdvSM) | SM With an Associated Hematologic Neoplasm (SM-AHN) | Mast Cell Leukemia (MCL) | Aggressive Systemic Mastocytosis (ASM)United States, Norway, Spain, Australia, Switzerland, Germany, Belgium, Netherlands, Canada, France, United Kingdom, Austria, Italy